Minaris maps out a manufacturing-first strategy under Orla Cloak

Minaris Advanced Therapies is using a recent PharmaShots interview with CEO Dr. Orla Cloak to sharpen its message around manufacturing discipline, scale, and integration as the company moves through its first year as a newly combined advanced-therapy business. Cloak described Minaris as operating through two linked units — Advanced Therapies, a cell and gene therapy CDMO, and Advanced Testing, a biosafety and analytical testing business — with the goal of supporting developers from early work through commercialization. That positioning follows Altaris’ March 2025 acquisition of WuXi Advanced Therapies’ U.S. and U.K. operations and Minaris Regenerative Medicine, and the formal launch of the combined Minaris Advanced Therapies brand in May 2025. Cloak was appointed CEO on July 21, 2025, after 17 years at Lonza. (minaris.com)

Why it matters: For veterinary professionals tracking the broader biologics and regenerative medicine supply chain, the interview is less about a single product announcement and more about where contract manufacturing is heading: tighter integration of manufacturing and testing, more emphasis on tech transfer and comparability, and a push to make complex autologous and allogeneic therapies more repeatable at scale. Those capabilities are being built for human cell and gene therapy, but they can influence standards, talent flow, quality systems, and partner expectations across adjacent animal health and regenerative medicine markets. Minaris says it brings more than 25 years of cell and gene therapy CDMO experience, more than 40 years in analytical and biosafety testing, 7,500-plus GMP batches, and testing support for more than 25 commercial products. (minaris.com)

What to watch: Watch for whether Minaris turns this strategy into new partnerships, commercial manufacturing wins, and clearer evidence that its combined manufacturing-and-testing model can shorten development timelines. (minaris.com)